February 16th 2024
The FDA has approved lifileucel, a tumor infiltrating lymphocyte therapy, for the treatment of advanced melanoma.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cabozantinib Prolongs Survival in Patients with Advanced Osteosarcoma and Ewing Sarcoma
November 20th 2018Cabozantinib demonstrated the strongest response observed to date among all the multikinase inhibitors that have shown activity in bone sarcoma, according to results from the CABONE trial that were reported at the 2018 CTOS Annual Meeting.
Read More
Phase III Trial for Patients With mCSCC Who Progress After First-line Chemotherapy
November 19th 2018Danny Rischin, MD, MBBS, FRACP, discusses an ongoing phase III trial for patients with metastatic cutaneous squamous cell carcinoma or recurrent disease after progressing on frontline chemotherapy.
Watch
SITC Recommendations Provide Guidance for Day-to-Day Management of Melanoma
November 15th 2018After decades of being considered the “graveyard of drug development,” melanoma has now become one of the hottest fields in oncologic research. In response to this rapid change in the treatment landscape, the Society for Immunotherapy of Cancer has issued updated consensus guidelines to help clinicians stratify patients, choose optimal treatment regimens, and manage immune-related adverse events in patients with stage II to IV disease.
Read More
CSCC Lesions Found in Few Patients Treated With PD-1/PD-L1 Checkpoint Inhibition
November 13th 2018An analysis of patients who presented to MD Anderson Cancer Center’s dermatology clinic following treatment with anti–PD-1/PD-L1 treatment suggests a potential association between the development of cutaneous squamous cell carcinoma lesions and PD-1/PD-L1 checkpoint inhibition.
Read More
A Primer on the Epidemiology and Pathophysiology of Cutaneous Squamous Cell Carcinoma
November 12th 2018Cutaneous squamous cell carcinoma is the second most common form of skin cancer, with an estimated 1 million cases treated in the United States each year. Although most cSCCs are localized and can be easily treated, approximately 5% of patients will experience local recurrence, 4% will develop nodal metastases, and up to 2% will die of the disease. In addition to the small but significant number of deaths attributed to cSCC each year, the disease and its associated precancerous skin lesions contribute to a large financial burden of more than $4.5 billion annually in the United States.
Read More
The Current and Future Treatment Landscape of Cutaneous Squamous Cell Carcinoma
November 12th 2018Although it is the second most common form of skin cancer in the United States, cutaneous squamous cell carcinoma can often be effectively treated with a variety of surgical modalities, such as standard excision, Mohs micrographic surgery, curettage and electrodessication, and cryosurgery.
Read More
Tawbi Highlights Adjuvant Options for Patients With Melanoma
November 10th 2018There has been a rapid expansion to the treatment landscape for adjuvant melanoma and there is no head-to-head comparative data for the challenge of selecting between immunotherapy and targeted therapy. When selecting a type of therapy, communicating relative merits and risks of both options to patients is necessary in making a shared decision, said Hussein Tawbi, MD, PhD.
Read More
Advanced CSCC Landscape Appears Promising After PD-1 Inhibitor Approval
November 9th 2018According to Anna C. Pavlick, BSM, MS, DO, MBA, the treatment landscape for cutaneous squamous cell carcinoma has changed dramatically in September 2018. During her session at the <em>36th Annual</em> CFS<sup>®</sup>, she said this is due to PD-1 inhibitor cemiplimab, the first agent approved specifically for advanced CSCC.
Read More
Despite Advances, Interpreting Data From Genomics and Precision Medicine Lags
October 25th 2018I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Read More
Financial Advocacy Grows Under the Value-Based System
October 24th 2018Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
Read More
ACCC President Reignites Resilience in Oncology Caregivers
October 23rd 2018Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Watch
Follow-Up Data Confirm RFS Benefit With Dabrafenib/Trametinib Combo in BRAF+ Melanoma
October 23rd 2018In long-term follow-up results from the COMBI-AD trial, the relapse-free survival benefit with adjuvant dabrafenib (Tafinlar) and trametinib (Mekinist) was confirmed in patients with resected stage III <em>BRAF</em>-mutant melanoma. The follow-up data were reported by Georgina Long, MBBS, PhD, during the 2018 ESMO Congress in Munich, Germany.
Read More
Larotrectinib Induces 80% ORR in Advanced NTRK+ Solid Tumors
October 22nd 2018Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
Read More